Literature DB >> 8551598

Immune system-dependent and -independent replication of the scrapie agent.

C I Lasmézas1, J Y Cesbron, J P Deslys, R Demaimay, K T Adjou, R Rioux, C Lemaire, C Locht, D Dormont.   

Abstract

Using the severe combined immunodeficiency (SCID) mouse model, we investigated the requirement of the immune system for the development of scrapie after peripheral inoculation. A total of 33% of SCID mice, all but one immunologically reconstituted SCID mice (93%), and all CB17 control mice developed the disease. PrPres was detectable in the brains of all diseased animals and in the spleens of reconstituted SCID and CB17 control mice but not of the diseased non-immunologically reconstituted SCID mice. The immune system appears to be a primary target in the pathogenesis of scrapie, but direct spread to the central nervous system from the peritoneum via visceral nerve fibers can probably also occur.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551598      PMCID: PMC189946     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Ionising radiation has no influence on scrapie incubation period in mice.

Authors:  H Fraser; C F Farquhar
Journal:  Vet Microbiol       Date:  1987-03       Impact factor: 3.293

2.  Organ distribution of proteinase-resistant prion protein in humans and mice with Creutzfeldt-Jakob disease.

Authors:  T Kitamoto; S Mohri; J Tateishi
Journal:  J Gen Virol       Date:  1989-12       Impact factor: 3.891

3.  A novel progressive spongiform encephalopathy in cattle.

Authors:  G A Wells; A C Scott; C T Johnson; R F Gunning; R D Hancock; M Jeffrey; M Dawson; R Bradley
Journal:  Vet Rec       Date:  1987-10-31       Impact factor: 2.695

4.  Scrapie-infected spleens: analysis of infectivity, scrapie-associated fibrils, and protease-resistant proteins.

Authors:  R Rubenstein; P A Merz; R J Kascsak; C L Scalici; M C Papini; R I Carp; R H Kimberlin
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

5.  Amphotericin B: a novel class of antiscrapie drugs.

Authors:  M Pocchiari; P Casaccia; A Ladogana
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

Review 6.  The SCID mouse mutant: definition, characterization, and potential uses.

Authors:  M J Bosma; A M Carroll
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

7.  Incubation periods in six models of intraperitoneally injected scrapie depend mainly on the dynamics of agent replication within the nervous system and not the lymphoreticular system.

Authors:  R H Kimberlin; C A Walker
Journal:  J Gen Virol       Date:  1988-12       Impact factor: 3.891

8.  Pathogenesis of scrapie in mice after intragastric infection.

Authors:  R H Kimberlin; C A Walker
Journal:  Virus Res       Date:  1989-03       Impact factor: 3.303

9.  Western blot detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice.

Authors:  S Doi; M Ito; M Shinagawa; G Sato; H Isomura; H Goto
Journal:  J Gen Virol       Date:  1988-04       Impact factor: 3.891

10.  Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions.

Authors:  R H Kimberlin; C A Walker
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

View more
  22 in total

1.  Autonomic nervous system innervation of lymphoid territories in spleen: a possible involvement of noradrenergic neurons for prion neuroinvasion in natural scrapie.

Authors:  A Bencsik; S Lezmi; T Baron
Journal:  J Neurovirol       Date:  2001-10       Impact factor: 2.643

2.  Architecture of secondary lymphoid tissue in sheep experimentally challenged with scrapie.

Authors:  Marie L Davies; Lee J Hopkins; Sue Halliday; Fiona Houston; Nora Hunter; Ian McConnell
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 3.  Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Authors:  Maria Caramelli; Giuseppe Ru; Pierluigi Acutis; Gianluigi Forloni
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.

Authors:  Carole Crozet; Yea-Lih Lin; Clément Mettling; Chantal Mourton-Gilles; Pierre Corbeau; Sylvain Lehmann; Véronique Perrier
Journal:  J Cell Sci       Date:  2004-10-19       Impact factor: 5.285

Review 5.  Prion diseases and the gastrointestinal tract.

Authors:  G A Davies; Adam R Bryant; John D Reynolds; Frank R Jirik; Keith A Sharkey
Journal:  Can J Gastroenterol       Date:  2006-01       Impact factor: 3.522

6.  Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells.

Authors:  P S Kaeser; M A Klein; P Schwarz; A Aguzzi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Plasma noradrenalin as marker of neuroinvasion in prion diseases.

Authors:  C Pollera; G Bondiolotti; E Formentin; M Puricelli; P Mantegazza; S Bareggi; G Poli; W Ponti
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

8.  Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro.

Authors:  Julia V Georgieva; Dharamdajal Kalicharan; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Dick Hoekstra; Inge S Zuhorn
Journal:  Mol Ther       Date:  2010-11-02       Impact factor: 11.454

9.  Opposite effects of dextran sulfate 500, the polyene antibiotic MS-8209, and Congo red on accumulation of the protease-resistant isoform of PrP in the spleens of mice inoculated intraperitoneally with the scrapie agent.

Authors:  V Beringue; K T Adjou; F Lamoury; T Maignien; J P Deslys; R Race; D Dormont
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 10.  Grafting mouse brains: from neurocarcinogenesis to neurodegeneration.

Authors:  A Aguzzi
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.